The second hypothesis concerned identifying which patients with hormone receptor-positive early breast cancer have a sufficiently good prognosis such that standard of care medical treatment, often comprising adjuvant endocrine therapy alone, was sufficient and which group should be considered for additional therapies. The gene discussed is NR4A1; the disease is breast cancer.